Results 191 to 200 of about 84,264 (300)

Phosphodiesterase Inhibitors in Fetal Growth Restriction: Do Not Forget to Consider Fetal Sex and Subcellular Compartmentation. [PDF]

Biomedicines
Peyter AC, Baud D, Tolsa JF.
europepmc   +1 more source

The Role of Phosphodiesterase Inhibitors in the Management of Cavernositis With Multifocal Abscesses: A Report of Case Series. [PDF]

Sex Med, 2020
Bakhsh A, Daqqaq T, Alhasan A, Alnazari M, Rajih E.   +4 more
europepmc   +1 more source

In Salmonella Typhimurium, YiiD Modulates cAMP Levels in Lag Phase During Growth on Succinate

Molecular Microbiology, EarlyView.
The YiiD enzyme, found by others to perform a redundant role in fatty acid biosynthesis, is found to be unexpectedly required for the early increase in cAMP in lag phase during growth on succinate. This intriguing finding suggests a mechanistic link may exist between fatty acid biosynthesis and catabolite repression. ABSTRACT In Salmonella Typhimurium (
John A. Ciemniecki, Jessica L. Will, Jorge C. Escalante‐Semerena   +2 more
wiley   +1 more source

The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review. [PDF]

Medicina (Kaunas)
Stamatiou K, Perletti G, Magri V, Trinchieri A.   +3 more
europepmc   +1 more source

Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation-induced deficits in spatial pattern separation. [PDF]

Synapse, 2020
Heckman PRA, Roig Kuhn F, Raven F, Bolsius YG, Prickaerts J, Meerlo P, Havekes R.   +6 more
europepmc   +1 more source

Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial (INTEGUMENT‐OLE)

Pediatric Dermatology, EarlyView.
ABSTRACT Background INTEGUMENT‐PED/NCT04845620, a 4‐week, phase 3 trial, demonstrated efficacy and safety of roflumilast cream 0.05% in children aged 2–5 years with mild‐to‐moderate atopic dermatitis (AD). A phase 3 open‐label extension trial (INTEGUMENT‐OLE [NCT04804605]) investigated long‐term outcomes continuing roflumilast cream for ≤ 56 weeks ...
Lawrence F. Eichenfield, Mercedes E. Gonzalez, Mark Boguniewicz, Tracy Funk, Adelaide A. Hebert, Vimal H. Prajapati, Chesahna Kindred, Rocco Serrao, Lisa Swanson, David Krupa, Scott Snyder, Melissa S. Seal, Diane Hanna, Patrick Burnett, David R. Berk   +14 more
wiley   +1 more source

Beyond traditional pharmacology: evaluating phosphodiesterase inhibitors in autism spectrum disorder. [PDF]

Neuropsychopharmacology
Padovan-Neto FE, Cerveira AJO, da Silva A, Ribeiro DL.   +3 more
europepmc   +1 more source

Effect and Mechanism of Phosphodiesterase Inhibitors on Trabecular Outflow. [PDF]

Korean J Ophthalmol, 2019
Kim JW, Lee JB, Lee SH.
europepmc   +1 more source

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis

EBioMedicine, 2016
Bintou Ahmadou Ahidjo, William R. Bishai
doaj   +1 more source

Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice. [PDF]

Nat Commun
Ajiboye J, Teixeira JE, Gasonoo M, Mattice EB, Korwin-Mihavics B, Miller P, Cameron AC, Stebbins E, Campbell SD, Griggs DW, Spangenberg T, Meyers MJ, Huston CD.   +12 more
europepmc   +1 more source